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Abstract
Non-syndromic congenital heart defects (CHDs) develop during embryogenesis as a result of a 
complex interplay between environmental exposures, genetics and epigenetic causes. Genetic 
factors associated with CHDs may be attributed to either independent effects of maternal or fetal 
genes, or the inter-generational interactions between maternal and fetal genes. Detecting gene-by-
gene interactions underlying complex diseases is a major challenge in genetic research. Detecting 
maternal-fetal genotype (MFG) interactions and differentiating them from the maternal/fetal main 
effects has presented additional statistical challenges due to correlations between maternal and 
fetal genomes. Traditionally, genetic variants are tested separately for maternal/fetal main effects 
and MFG interactions on a single-locus basis. We conducted a haplotype-based analysis with a 
penalized logistic regression framework to dissect the genetic effect associated with the 
development of non-syndromic conotruncal heart defects (CTD). Our method allows simultaneous 
model selection and effect estimation, providing a unified framework to differentiate maternal/
fetal main effect from the MFG interaction effect. In addition, the method is able to test multiple 
highly linked SNPs simultaneously with a configuration of haplotypes, which reduces the data 
dimensionality and the burden of multiple testing. By analyzing a dataset from the National Birth 
Defects Prevention Study (NBDPS), we identified seven genes (GSTA1, SOD2, MTRR, AHCYL2, 
GCLC, GSTM3 and RFC1) associated with the development of CTDs. Our findings suggest that 
MFG interactions between haplotypes in 3 of 7 genes, GCLC, GSTM3 and RFC1, are associated 
with non-syndromic conotruncal heart defects.
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1. INTRODUCTION
Genetic interactions, or epistatic effects, are believed to exist pervasively in biological 
pathways [Moore 2003]. Maternal-fetal genotype (MFG) interaction is a particular type of 
interaction, which occurs when an MFG combination jointly alters the phenotype or risk of 
disease in offspring. A well-known example of an MFG interaction is Rh incompatibility 
[Kulich and Kout 1967]. The Rh locus on chromosome 1p35 is bi-allelic with a null allele 
and a coding allele. Individuals homozygous for the null allele are Rh-negative, while those 
with a coding allele are Rh-positive. Rh incompatibility occurs between an Rh-negative 
mother and her Rh-positive fetus, because the mother can produce immune antibodies to the 
Rh antigens on the fetal red blood cells at birth, leading to Rh isoimmunization. Rh 
isoimmunization may have severe adverse effects, including anemia, hyperbilirubinemia, 
fetal hydrops and adverse fetal neurodevelopment [van Gent, et al. 1997]. Over the past 
decade, evidence has accumulated demonstrating that MFG interactions may be a common 
mechanism for various complex human diseases and birth defects, such as neural tube 
defects [Relton, et al. 2004], schizophrenia [Palmer, et al. 2002] and autism [Zandi, et al. 
2006]. Discovering and characterizing MFG interactions will contribute significantly to 
increasing our understanding of the etiology of birth defects and improving both maternal 
and fetal health.
Congenital heart defects (CHDs) are the most common type of birth defect with an 
estimated incidence of 6–8 per 1,000 live births [Hoffman and Kaplan 2002]. We and others, 
using candidate gene and pathway studies have identified maternal and fetal genetic 
susceptibilities that are associated with CHDs [Goldmuntz, et al. 2008; Hobbs, et al. 2011; 
Wessels and Willems 2010]. Though it is natural to wonder how pervasively MFG 
interactions exist, and how many possible interactive mechanisms there are [Sinsheimer, et 
al. 2010], relatively few studies have been conducted to detect the MFG interaction in regard 
to the development of CHDs [Lupo, et al. 2010].
Congenital heart defects are classified into various subgroups. Conotruncal heart defects 
(CTDs), a large subgroup of CHD, includes truncus arteriosus, transposition of the great 
arteries, double outlet right ventricle, tetralogy of fallot, pulmonary atresia, malalignment 
ventricle septal defect, and interrupted aortic arch. CTDs are among the most common and 
severe birth defects worldwide. Although survival of infants with CTDs has increased 
significantly over the last few decades, both mortality and morbidity remain high for these 
affected infants [van der Linde, et al. 2011]. Understanding the genetic mechanism 
underlying CTDs is of great importance to reduce morbidity and mortality related to these 
defects.
A potential difficulty encountered when evaluating the impact of genotypes from mother-
offspring pairs is the correlation between maternal and fetal genotypes. Independent 
analyses of maternal or fetal effects are likely to confound each other, such that a single 
model that simultaneously includes both maternal and fetal effects is preferred [Shi, et al. 
2008]. In pioneering work, a log-linear model was proposed to differentiate fetal genetic 
effects from maternally mediated genetic effects [Umbach and Weinberg 2000; Weinberg, et 
al. 1998; Wilcox, et al. 1998]. Since then, a number of methods have been proposed to 
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investigate the possible MFG interaction effect by extending the log-linear model 
[Ainsworth, et al. 2011; Childs, et al. 2010; Sinsheimer, et al. 2003]. These log-linear-based 
methods typically divided family samples into different strata by their parental mating 
genotype combinations, and model the number of cases and controls in each stratum 
assuming a Poisson distribution. The maternal effects, fetal effects and MFG interaction 
effects can be specified by various parameters, which are further estimated by maximizing 
the likelihood function. These proposed methods have been useful tools for association 
studies with mother-offspring genotype data. Because the fetal effect is estimated 
conditionally on parental genotypes, it is robust to population stratification.
Recently, we and others proposed a penalized logistic regression approach to detect single 
SNP-SNP interactions and two-SNP haplotype-haplotype interactions [Li, et al. 2010; Li, et 
al. 2009]. Our method utilized Least Absolute Shrinkage and Selection Operator (LASSO), a 
machine learning technique that allows simultaneous effect estimation and variable 
selection. In this article, we extend our previously developed method to detect multi-SNP 
haplotype-haplotype interactions in the context of mother-offspring pair data. Our proposed 
method has several appealing properties. First, the LASSO estimator provides an automatic 
inference for the underlying genetic mechanisms. No individual test is required to 
differentiate maternal, fetal and MFG interaction effect. Second, the proposed method is 
nested with a haplotype phasing strategy, which simultaneously handles multiple SNPs that 
are in Linkage Disequilibrium (LD). Such a haplotype analysis strategy may potentially 
yield more information than single SNPs alone [Wang, et al. 2012], and reduce the burden 
of multiple testing. In this study, we applied the proposed method to dissect the maternal, 
fetal and MFG interaction effect associated with CTDs using genetic data from a candidate 
gene study. We identified a number of haplotype blocks with potential association to CTD, 
and adjusted for multiple testing by the number of blocks instead of number of SNPs. 
Finally, we explore the possible mechanisms in regard to the MFG combinations that jointly 
alter the disease risk.
2. METHODS
2.1 Study Population
The dataset was part of the National Birth Defects Prevention Study (NBDPS), a large-scale 
case control study covering an annual birth population of 482,000, or 10% of U.S. births. 
CTD cases were ascertained from birth defect registries in ten participating states that had 
identical inclusion criteria: Arkansas, California, Georgia, Iowa, Massachusetts, New Jersey, 
New York, North Carolina, Texas, and Utah. All offspring, including both cases and 
controls, were born between 1997 and 2010. A detailed description of NBDPS methods have 
previously been published [Gallagher, et al. 2011; Rasmussen, et al. 2002; Yoon, et al. 
2001]. In this study, we included all available genotyped mother-offspring pairs, including 
331 case pairs and 875 control pairs. Case pairs were defined as those where the child had a 
conontruncal heart structural malformation, whereas control pairs were defined as those 
where the child did not have any structural birth defect. Maternal characteristics were 
similar between cases and controls (Table I).
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2.2 Genotyping and Quality Control
Our research team commissioned a custom panel of 1,536 SNPs covering 62 genes in the 
homocysteine, folate, and transsulfuration pathways potentially related to the development 
of CHD, using the Illumina GoldenGate custom genotyping platform, as described by 
Chowdhury et al. [Chowdhury, et al. 2012]. The whole genome amplified DNA was used 
for genotyping. Initial genotype calls were generated using GenCall, Illumina’s proprietary 
algorithm, with subsequent analysis performed using SNPMClust, a bivariate Gaussian 
model-based genotype clustering and calling algorithm developed in-house. To ensure high-
quality genotypes, we applied stringent quality control measures and excluded SNPs with 
obviously poor clustering behavior (60 SNPs), no-call rates > 10% (328 SNPs), Mendelian 
error rates > 5% (11 SNPs), minor allele frequencies < 5% (204 SNPs), or significant 
deviation from Hardy-Weinberg Equilibrium in at least one racial group (p < 10e-4, 12 
SNPs). After genotyping and subsequent quality control checks, genotyping data was 
available for 921 bi-allelic SNPs in 60 candidate genes for each mother-child pair.
2.3 Determination of Haplotype Blocks
The haplotype blocks were phased by using software Haploview version 4.2 [Barrett, et al. 
2005]. Linkage Disequilibrium (LD) was first measured by the D′ statistic between two 
neighboring genetic variants. The Solid Spine of LD criterion, an internally developed 
method by Haploveiw, was further used to determine the haplotype blocks by using a 
threshold of D′ > 0.6. After applying Haploview, a total number of 112 haplotype blocks 
were identified for association analysis.
2.4 Statistical Method
We previously proposed a penalized logistic regression approach to detect two-SNP 
haplotype-haplotype interactions [Li, et al. 2010], and through simulations showed that the 
method has a low false positive rate and reasonable power for detecting haplotype-haplotype 
interactions. In this article, we briefly explain our method in the context of a flexible number 
of SNPs, more theoretical details can be found elsewhere [Cui, et al. 2007; Li, et al. 2010].
Assume we have a study population of n mother-offspring pairs, with n1 case pairs and n0 
control pairs (n = n1 + n0). Denote yi as the disease status for the i-th mother-offspring pair; 
yi = 1 for case and yi = 0 for control. Suppose we are interested in a particular haplotype 
block with K bi-allelic loci that are in LD. Two alleles at the k-th locus may form three 
possible genotypes, denoted as AkAk, AkBk and BkBk ; 1 ≤ k ≤ K.
Mapping Composite Diplotypes—Without loss of generality, denote H=[A1A2 ……
AK] as a “risk” haplotype that may alter the likelihood of disease. The K-locus genotype 
within the haplotype block can then be mapped into three possible composite diplotypes, 
namely HH, HH̅ and H̅H̅; where H̅ represents all haplotypes that are different from the 
“risk” haplotype H. The haplotype block may have a large number of multi-locus genotypes 
(i.e. up to 3K). However, the number of composite diplotypes is always reduced to three 
after the haplotype configuration, which significantly lessens data dimensionality. It is 
worthwhile to note that a “risk” haplotype is defined here for the purpose of dimension 
reduction. In practice, a “risk” haplotype may have a protective effect that corresponds to a 
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lower likelihood of disease. Such a modeling strategy was also adopted in previous studies 
[Lin, et al. 2007; Liu, et al. 2004; Liu, et al. 2011; Zhang, et al. 2012]. A potential challenge 
for the diplotype mapping is phase-ambiguity. The phase-ambiguous genotypes were treated 
as missing data, and phase determined probabilistically via an expectation-maximization 
(EM) algorithm described below.
In practice, every haplotype with an appreciable frequency (e.g. greater than 5%) may serve 
as a potential “risk” haplotype. Different choices of “risk” haplotypes would lead to various 
mapping strategies for composite diplotypes. The haplotype that gives the best model fit 
(minimum BIC statistic described below) will be selected as the optimal “risk” haplotype.
Epistasis Model—Denote the composite diplotypes for the i-th mother-offspring pair as 
Gi,m for the mother’s diplotype and Gi,f for the fetus’s diplotype. We use a logistic 
regression framework to model the genetic effects of the maternal block, the fetal block and 
their possible interactions:
Eq. 
(1)
and xi,f and zi,f are similarly defined. This coding strategy follows Cockerham’s orthogonal 
partition method [Cockerham 1954; Kao and Zeng 2002] where am(f) and dm(f) can be 
interpreted as the additive and dominance effects for the risk haplotype at a maternal (fetal) 
block; iaa, iad, ida, and idd can be interpreted as the additive × additive, additive × 
dominance, dominance × additive, and dominance × dominance interaction effect between 
the maternal and fetal blocks, respectively.
The coefficients of genetic effect, β = (am,af,dm,df, iaa, iad, ida, idd), are estimated by 
minimizing the −2 times log-likelihood with an adaptive LASSO penalty.
Eq. (2)
Where L is the log-likelihood; λ is a tuning parameter between the likelihood and penalty 
term, and is chosen to minimize Bayesian Information Criterion (BIC); ωj is a weight 
corresponding to the j-th genetic effect, 1 ≤ j ≤ 8, and is chosen as the j-th component of 1/
βMLE; where βMLE is the maximum likelihood estimate of β. Previous studies have shown 
that the coefficients estimated using this adaptive LASSO are consistent and thus 
asymptotically converge to their true values [Zou 2006].
MFG combinations and Likelihood Function—For simplicity, we first assume that all 
multi-locus genotypes are phase-known, and each can be mapped to a unique composite 
diplotype. Consistent with Mendelian transmission, seven maternal-fetal genotypes (MFG) 
combinations may be formed and numerically denoted as 11, 12, 21, 22, 23, 32, 33 (Table 
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II). Further, for each MFG combination, a likelihood function can be calculated according to 
the logistic regression model in Eq. (1). For example, if the i-th mother-offspring pair has 
MFG=11 (i.e. Gi,m = HH and Gi,f = HH), its likelihood of being a case pair is:
Eq. (3)
and its likelihood of being a control pair is:
The likelihood for other MFG combinations can be calculated.
If the multi-locus genotype Gi,m and Gi,f is phase-ambiguous, then it will map to two 
possible composite diplotypes, HH ̅ or H ̅H̅. To construct the likelihood function in Eq. (2), 
we define a set of indicator variables for MFG combinations as:
Di,12, Di,21, Di,22, Di,23, Di,32, and Di,33 can be defined similarly. Then the likelihood 
function in Eq. (2) takes the following form:
Because of phase-ambiguity, the indicators, Di,11…Di,33, are treated as missing data, and the 
likelihood function above is maximized iteratively with an EM algorithm. The 
computational details can be found in Li et al. [Li, et al. 2010].
After the coefficients are estimated, the likelihood of being a case pair can be computed for 
each MFG combination. It should be noted that the adaptive LASSO simultaneously 
estimates parameters and performs model selection through shrinkage. Coefficients that do 
not significantly differ from 0 are expected to be shrunk to 0. As a result, some of the MFG 
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combinations may have the same likelihood of disease. Given a simple example when the 
maternal additive effect is the only no-zero coefficient (e.g. am ≠ 0,dm = af = df = iaa = iad = 
ida = idd = 0), the MFG combinations in the same row of Table II would have the same 
likelihood of disease. According to Eq. (3), the 7 maternal/fetal genotype combinations can 
be partitioned into 3 risk groups:
R1 = {H̅H̅ / HH̅; H̅H̅ / H ̅H̅} with a likelihood of disease as ;
R2 = {HH̅ / HH̅; HH̅ / HH̅; HH ̅ / H̅H̅} with a likelihood of disease as ;
R3 = {HH / HH; HH / HH̅} with a likelihood of disease as .
When the coefficient am is positive, group R1 would have the lowest likelihood of disease 
and can be denoted as a reference group. Compared to group R1, group R2 and R3 would 
have increased risks of disease with odds ratios (OR) of exp(am) and exp(2am), respectively. 
Standard errors and thus confidence intervals for the OR are computed using bootstrap 
resampling [Tibshirani 1996]. Partitioning of risk groups with other non-zero coefficients 
can be obtained in a similar fashion and are not detailed here.
3. RESULTS
Using Haploview, we identified 112 haplotype blocks for analysis [Barrett, et al. 2005]. 
Within each block, all haplotypes with a frequency greater than 5% were examined as 
potential “risk” haplotypes, and the haplotype with a minimum BIC was selected as the 
optimal “risk” haplotype. Application of our method identified 7 haplotype blocks with non-
zero coefficients, indicating a potentially significant genotype-phenotype association. The 
identified blocks were located in 7 genes: GSTA1, GCLC, SOD2, GSTM3, MTRR, AHCYL2 
and RFC1. Information for the identified haplotypes is summarized in Table III. The 
frequencies of “risk” haplotypes were estimated based on the entire study population, 
including both cases and controls.
The LASSO estimator provides a direct inference of the underlying genetic mechanism. 
Based on the non-zero coefficients, the 7 identified blocks fell into three possible categories: 
maternal main effect (i.e. am,dm ≠ 0), fetal main effect (af,df ≠ 0), or MFG interaction effect 
(i.e. iaa, iad, ida, idd ≠ 0). To further investigate the underlying genetic mechanisms, the 
likelihood of being a case pair was estimated for each MFG combination. The seven 
possible MFG combinations were partitioned into various risk groups according to their 
likelihoods of disease, as exemplified in method section. For simplicity, the risk group with 
the lowest likelihood of disease was used as reference group. The odds ratios (ORs), 
corresponding 95% confidence intervals and p-values were empirically estimated by using 
100 bootstrap samples. The results are summarized in Table IV. All identified haplotype 
blocks had empirical p-values significant at the nominal level of 5%. We further applied the 
Storey’s q-value method to adjust for the multiple testing of 112 blocks [Storey 2002]. 
Although all 7 blocks had a false discovery rate (FDR) < = 0.25, only two blocks remained 
significant with a FDR less than 5%. These blocks were located within the glutathione S-
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transferase alpha 1 (GSTA1) and the glutamate-cysteine ligase, catalytic subunit (GCLC) 
genes. Three genetic mechanisms were observed for the identified haplotype blocks.
1) Two blocks exhibited maternal main effect only
The results are summarized in Table IV. One block with 3 SNPs was located within the 
GSTA1 gene on chromosome 6. The haplotype structure showed three highly linked SNPs, 
rs9474321, rs6917325 and rs10948723, covering an 18 KB region (Figure 1A). Further, the 
MFG combinations were partitioned into two risk groups. Four MFG combinations had 
relatively lower likelihood of disease, and were used as reference group. We denoted the 
maternal/fetal genotype combinations in the reference group as R1 = {HH / HH; HH / HH̅; 
H̅H̅ / HH̅; H̅H̅ / H̅H̅}. Compared to the reference group, three other MFG combinations had 
an elevated likelihood of disease, denoted as R2 = {HH̅ / HH; HH̅ / HH̅; HH̅ / H̅H̅}. The 
corresponding OR between R1 and R2 was estimated to be 1.50 (95% CI: 1.18, 1.89). In 
such a scenario, the maternal haplotype H showed dominance effect that will increase the 
risk of disease, while the risk of disease was unchanged by fetal genotypes (Figure 1B). 
Similarly, our results show that a maternal haplotype of 6 SNPs within the gene SOD2 
(Figure 2) may have an additive effect that increases the risk of disease.
2) Two blocks exhibited fetal main effect only
Two blocks were located within gene MTRR and AHCYL2, comprising 2 and 7 SNPs, 
respectively. The results are summarized in Table IV. For both blocks, the MFG 
combinations can be partitioned into three risk groups, according to the fetal genotypes. In 
each block, a fetal haplotype H showed an additive effect that was protective of the disease. 
The disease risk increased as the copy of haplotype decreased in the fetal genome, and was 
unchanged with maternal genotypes. We illustrated the pattern in Figure 3–4.
3) Three blocks exhibited MFG interaction effect
Three blocks were identified with MFG interaction effect (i.e. iaa, iad, ida, idd ≠ 0). These 
three blocks were located within genes GCLC, RFC1 and GSTM3, respectively on 
chromosome 6, 4, and 1. The results were summarized in Table IV. The block within gene 
GCLC had the most complicated interactive mechanisms. This block comprised 16 SNPs, 
covering a 22 KB region on chromosome 6. Based on the estimated coefficients, the MFG 
combinations were partitioned into 5 risk groups. As illustrated in Figure 5, when maternal 
genotype was HH̅, the risk of disease was unchanged with the fetal genotypes. However, 
when maternal genotype was HH (H̅H̅), the risk of disease showed increasing (decreasing) 
pattern with the fetal genotype. This pattern of “cross-over” was an indication of the 
potential MFG interaction effect. Similarly, the interactive pattern of the blocks in gene 
RFC1 and GSTM3 is illustrated in Figure 6–7.
4. DISCUSSION
Complex diseases are increasingly seen to be caused by the interplay of multiple genetic 
variants and environmental factors through complicated mechanisms. Detecting gene-gene 
interactions has been a major difficulty in genetic association studies [Cordell 2009], and 
can be especially challenging in maternal and perinatal research. Two types of gene-gene 
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interactions are possible during pregnancy: intra-generational interaction within either 
maternal or fetal genome, and inter-generational interaction between maternal and fetal 
genomes. The inter-generational effect may lead to either conflicting or beneficial 
environment for fetal growth, which may influence the phenotypes of both mothers and 
babies [Sinsheimer, et al. 2010]. In addition, both maternal and fetal genes may have non-
interactive main effects associated with the phenotypes. The effects of maternal genes may 
influence maternal metabolites, which are associated with the risk of having a CHD-affected 
pregnancy. For example, previous studies by our research group and others have described 
an association between gene MTHFR polymorphisms and maternal homocysteine levels that 
affect the risk of congenital anomalies [Botto and Yang 2000; Hobbs, et al. 2006]. 
Meanwhile, the correlation between maternal and fetal genomes imposes great difficulties 
on the statistical analyses to differentiate maternal, fetal and MFG interaction effects. In this 
study, we adopt a haplotype-based method, which utilizes a logistic regression framework 
with adaptive LASSO. This method serves to estimate maternal, fetal and MFG interaction 
effects, and allows modeling of multiple SNPs within a haplotype block simultaneously, 
thus reducing the burden of multiple testing. Using this method to examine the association 
between haplotypes in 60 candidate genes and the occurrence of CTD, we identified 7 genes 
potentially associated with this birth defect. Further analyses of these results suggest that the 
identified genes may influence the phenotype through various genetic mechanisms, 
corresponding to maternal main effect, fetal main effect and MFG interaction effects.
In our result, haplotypes within two genes, the glutathione S-transferase alpha 1 (GSTA1) 
and the glutamate-cysteine ligase, catalytic subunit (GCLC), were significantly associated 
with the occurrence of CTDs at a FDR level of 5%. The haplotype within the GSTA1 gene 
exhibited a significant maternal main effect only. This gene belongs to the Glutathione S-
Transferase family, and its enzyme plays a key role in the detoxification of many toxic 
compounds [Coles and Kadlubar 2005]. A recent study in an Italian population also found 
that maternal variation in GSTA1 is associated with the risk of recurrent miscarriage 
[Polimanti, et al. 2012]. The haplotype within the GCLC gene exhibited both a significant 
maternal main effect and a significant MFG interaction effect. This gene encodes an enzyme 
for glutathione synthesis, thereby, preventing damage from oxidative stress. Variants with 
GCLC are known to make the enzyme less biologically active and lead to increased 
oxidative stress that may alter embryongenic processes. Population-based association studies 
have found an association between GCLC variants and cardiovascular events, such as 
myocardial infarction [Campolo, et al. 2007; Koide, et al. 2003].
In the current study, we also identified haplotypes in five additional genes, SOD2, GSTM3, 
MTRR, AHCYL2 and RFC1, potentially associated with CTDs, although the overall FDR for 
these 5 genes exceeded the 5% threshold. This is partly due to the limited sample size of our 
study (i.e. 331 case pairs and 875 control pairs), especially for the number of case pairs. We 
expect the power to increase in our on-going follow-up studies with larger sample sizes, 
which will improve the overall FDR. Considering the fact that most of them are functionally 
related to cardiovascular outcomes, we think that these genes may also play a role in the 
development of CTD, and are worth examining in further studies.
Li et al. Page 9
Genet Epidemiol. Author manuscript; available in PMC 2015 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
A few limitations should also be noted. First, the current study only included common SNPs 
that have minor allele frequencies (MAFs) of 5% or higher. Evidence from Phase III of the 
International HapMap Project and 1,000 Genome Project have supported that rare variants 
with lower MAFs may contribute considerately to the development of complex human 
diseases [Abecasis, et al. 2012; Altshuler, et al. 2010]. However, because of their low 
MAFs, the rare variants are less easy to be phased through LD blocks, and were not included 
in the current haplotype analysis. Second, the genetic etiology of non-syndromic CTDs may 
be highly complex, involving both inter-generational and intra-generational interactions 
among genes from either different genomes or different genomic regions. Our current 
analysis only considered the inter-generational interactions between maternal and fetal genes 
from the same genomic region (LD block). While MFG interactions may also exist between 
genes from different genomic regions, investigation of these interactions will significantly 
increase the number of statistical tests and is beyond the scope of the current study.
ACKNOWLEDGMENTS
The authors wish to thank the generous participation of the numerous families that made this research study 
possible. We also thank the Centers for Birth Defects Research and Prevention in Arkansas, California, Georgia, 
Iowa, Massachusetts, New Jersey, New York, North Carolina, Texas, and Utah for their contribution of data and 
manuscript review. The authors also want to thank Ashley S. Block for assistance in the preparation of this 
manuscript, and the anonymous reviewers for valuable suggestions.
This work is supported by the National Institute of Child Health and Human Development (NICHD) under award 
number 5R01HD039054-12, the National Center on Birth Defects and Developmental Disabilities (NCBDDD) 
under award number 5U01DD000491-05, and the Arkansas Biosciences Institute. The contents are solely the 
responsibility of the authors and do not necessarily represent the official views of the Center of Disease Control and 
Prevention (CDC).
REFERENCE
Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, 
McVean GA. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012; 
491(7422):56–65. [PubMed: 23128226] 
Ainsworth HF, Unwin J, Jamison DL, Cordell HJ. Investigation of maternal effects, maternal-fetal 
interactions and parent-of-origin effects (imprinting), using mothers and their offspring. Genet 
Epidemiol. 2011; 35(1):19–45. [PubMed: 21181895] 
Altshuler DM, Gibbs RA, Peltonen L, Altshuler DM, Gibbs RA, Peltonen L, Dermitzakis E, Schaffner 
SF, Yu F, Peltonen L, et al. Integrating common and rare genetic variation in diverse human 
populations. Nature. 2010; 467(7311):52–58. [PubMed: 20811451] 
Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype 
maps. Bioinformatics. 2005; 21(2):263–265. [PubMed: 15297300] 
Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: 
a HuGE review. Am J Epidemiol. 2000; 151(9):862–877. [PubMed: 10791559] 
Campolo J, Penco S, Bianchi E, Colombo L, Parolini M, Caruso R, Sedda V, Patrosso MC, Cighetti G, 
Marocchi A, et al. Glutamate-cysteine ligase polymorphism, hypertension, and male sex are 
associated with cardiovascular events. Biochemical and genetic characterization of Italian 
subpopulation. Am Heart J. 2007; 154(6):1123–1129. [PubMed: 18035085] 
Childs EJ, Palmer CG, Lange K, Sinsheimer JS. Modeling maternal-offspring gene-gene interactions: 
the extended-MFG test. Genet Epidemiol. 2010; 34(5):512–521. [PubMed: 20552637] 
Chowdhury S, Hobbs CA, MacLeod SL, Cleves MA, Melnyk S, James SJ, Hu P, Erickson SW. 
Associations between maternal genotypes and metabolites implicated in congenital heart defects. 
Mol Genet Metab. 2012; 107(3):596–604. [PubMed: 23059056] 
Li et al. Page 10
Genet Epidemiol. Author manuscript; available in PMC 2015 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Cockerham CC. An Extension of the Concept of Partitioning Hereditary Variance for Analysis of 
Covariances among Relatives When Epistasis Is Present. Genetics. 1954; 39(6):859–882. [PubMed: 
17247525] 
Coles BF, Kadlubar FF. Human alpha class glutathione S-transferases: genetic polymorphism, 
expression, and susceptibility to disease. Methods Enzymol. 2005; 401:9–42. [PubMed: 
16399377] 
Cordell HJ. Detecting gene-gene interactions that underlie human diseases. Nat Rev Genet. 2009; 
10(6):392–404. [PubMed: 19434077] 
Cui Y, Fu W, Sun K, Romero R, Wu R. Mapping Nucleotide Sequences that Encode Complex Binary 
Disease Traits with HapMap. Curr Genomics. 2007; 8(5):307–322. [PubMed: 19384427] 
Gallagher ML, Sturchio C, Smith A, Koontz D, Jenkins MM, Honein MA, Rasmussen SA. Evaluation 
of mailed pediatric buccal cytobrushes for use in a case-control study of birth defects. Birth 
Defects Res A Clin Mol Teratol. 2011; 91(7):642–648. [PubMed: 21630425] 
Goldmuntz E, Woyciechowski S, Renstrom D, Lupo PJ, Mitchell LE. Variants of folate metabolism 
genes and the risk of conotruncal cardiac defects. Circ Cardiovasc Genet. 2008; 1(2):126–132. 
[PubMed: 20031554] 
Hobbs CA, James SJ, Jernigan S, Melnyk S, Lu Y, Malik S, Cleves MA. Congenital heart defects, 
maternal homocysteine, smoking, and the 677 C>T polymorphism in the 
methylenetetrahydrofolate reductase gene: evaluating gene-environment interactions. Am J Obstet 
Gynecol. 2006; 194(1):218–224. [PubMed: 16389035] 
Hobbs CA, MacLeod SL, Jill James S, Cleves MA. Congenital heart defects and maternal genetic, 
metabolic, and lifestyle factors. Birth Defects Res A Clin Mol Teratol. 2011; 91(4):195–203. 
[PubMed: 21384532] 
Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002; 39(12):
1890–1900. [PubMed: 12084585] 
Kao CH, Zeng ZB. Modeling epistasis of quantitative trait loci using Cockerham's model. Genetics. 
2002; 160(3):1243–1261. [PubMed: 11901137] 
Koide S, Kugiyama K, Sugiyama S, Nakamura S, Fukushima H, Honda O, Yoshimura M, Ogawa H. 
Association of polymorphism in glutamate-cysteine ligase catalytic subunit gene with coronary 
vasomotor dysfunction and myocardial infarction. J Am Coll Cardiol. 2003; 41(4):539–545. 
[PubMed: 12598062] 
Kulich V, Kout M. Hemolytic disease of a newborn caused by anti-k antibody. Cesk Pediatr. 1967; 
22(9):823–826. [PubMed: 5584080] 
Li M, Romero R, Fu WJ, Cui Y. Mapping haplotype-haplotype interactions with adaptive LASSO. 
BMC Genet. 2010; 11:79. [PubMed: 20799953] 
Li S, Lu Q, Fu W, Romero R, Cui Y. A regularized regression approach for dissecting genetic conflicts 
that increase disease risk in pregnancy. Stat Appl Genet Mol Biol. 2009; 8 Article 45. 
Lin M, Li H, Hou W, Johnson JA, Wu R. Modeling sequence-sequence interactions for drug response. 
Bioinformatics. 2007; 23(10):1251–1257. [PubMed: 17392331] 
Liu T, Johnson JA, Casella G, Wu R. Sequencing complex diseases With HapMap. Genetics. 2004; 
168(1):503–511. [PubMed: 15454560] 
Liu T, Thalamuthu A, Liu JJ, Chen C, Wang Z, Wu R. Asymptotic distribution for epistatic tests in 
case-control studies. Genomics. 2011; 98(2):145–151. [PubMed: 21620949] 
Lupo PJ, Goldmuntz E, Mitchell LE. Gene-gene interactions in the folate metabolic pathway and the 
risk of conotruncal heart defects. J Biomed Biotechnol. 2010; 2010:630940. [PubMed: 20111745] 
Moore JH. The ubiquitous nature of epistasis in determining susceptibility to common human diseases. 
Hum Hered. 2003; 56(1–3):73–82. [PubMed: 14614241] 
Palmer CG, Turunen JA, Sinsheimer JS, Minassian S, Paunio T, Lonnqvist J, Peltonen L, Woodward 
JA. RHD maternal-fetal genotype incompatibility increases schizophrenia susceptibility. Am J 
Hum Genet. 2002; 71(6):1312–1319. [PubMed: 12439825] 
Polimanti R, Piacentini S, Lazzarin N, Vaquero E, Re MA, Manfellotto D, Fuciarelli M. Glutathione 
S-transferase genes and the risk of recurrent miscarriage in Italian women. Fertil Steril. 2012; 
98(2):396–400. [PubMed: 22633257] 
Li et al. Page 11
Genet Epidemiol. Author manuscript; available in PMC 2015 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Rasmussen SA, Lammer EJ, Shaw GM, Finnell RH, McGehee RE Jr, Gallagher M, Romitti PA, 
Murray JC. National Birth Defects Prevention S. Integration of DNA sample collection into a 
multi-site birth defects case-control study. Teratology. 2002; 66(4):177–184. [PubMed: 12353214] 
Relton CL, Wilding CS, Pearce MS, Laffling AJ, Jonas PA, Lynch SA, Tawn EJ, Burn J. Gene-gene 
interaction in folate-related genes and risk of neural tube defects in a UK population. J Med Genet. 
2004; 41(4):256–260. [PubMed: 15060097] 
Shi M, Umbach DM, Vermeulen SH, Weinberg CR. Making the most of case-mother/control-mother 
studies. Am J Epidemiol. 2008; 168(5):541–547. [PubMed: 18650222] 
Sinsheimer JS, Elston RC, Fu WJ. Gene-gene interaction in maternal and perinatal research. J Biomed 
Biotechnol. 2010; 2010
Sinsheimer JS, Palmer CG, Woodward JA. Detecting genotype combinations that increase risk for 
disease: maternal-fetal genotype incompatibility test. Genet Epidemiol. 2003; 24(1):1–13. 
[PubMed: 12508251] 
Storey JD. A direct approach to false discovery rates. J. Roy. Stat. Soc. Ser. B. 2002; 64:479–498.
Tibshirani R. Regression Shrinkage and Selection Via the Lasso. Journal of the Royal Statistical 
Society. Series B. 1996; 58:267–288.
Umbach DM, Weinberg CR. The use of case-parent triads to study joint effects of genotype and 
exposure. Am J Hum Genet. 2000; 66(1):251–261. [PubMed: 10631155] 
van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, Roos-
Hesselink JW. Birth prevalence of congenital heart disease worldwide: a systematic review and 
meta-analysis. J Am Coll Cardiol. 2011; 58(21):2241–2247. [PubMed: 22078432] 
van Gent T, Heijnen CJ, Treffers PD. Autism and the immune system. J Child Psychol Psychiatry. 
1997; 38(3):337–349. [PubMed: 9232480] 
Wang X, Morris NJ, Schaid DJ, Elston RC. Power of single- vs. multi-marker tests of association. 
Genet Epidemiol. 2012; 36(5):480–487. [PubMed: 22648939] 
Weinberg CR, Wilcox AJ, Lie RT. A log-linear approach to case-parent-triad data: assessing effects of 
disease genes that act either directly or through maternal effects and that may be subject to 
parental imprinting. Am J Hum Genet. 1998; 62(4):969–978. [PubMed: 9529360] 
Wessels MW, Willems PJ. Genetic factors in non-syndromic congenital heart malformations. Clin 
Genet. 2010; 78(2):103–123. [PubMed: 20497191] 
Wilcox AJ, Weinberg CR, Lie RT. Distinguishing the effects of maternal and offspring genes through 
studies of "case-parent triads". Am J Epidemiol. 1998; 148(9):893–901. [PubMed: 9801020] 
Yoon PW, Rasmussen SA, Lynberg MC, Moore CA, Anderka M, Carmichael SL, Costa P, Druschel 
C, Hobbs CA, Romitti PA, et al. The National Birth Defects Prevention Study. Public Health Rep. 
2001; 116(Suppl 1):32–40. [PubMed: 11889273] 
Zandi PP, Kalaydjian A, Avramopoulos D, Shao H, Fallin MD, Newschaffer CJ. Rh and ABO 
maternal-fetal incompatibility and risk of autism. Am J Med Genet B Neuropsychiatr Genet. 2006; 
141B(6):643–647. [PubMed: 16856119] 
Zhang L, Liu R, Wang Z, Culver DA, Wu R. Modeling haplotype-haplotype interactions in case-
control genetic association studies. Front Genet. 2012; 3:2. [PubMed: 22303409] 
Zou H. The adaptive LASSO and its oracle properties. JASA. 2006; 101:1418–1429.
Li et al. Page 12
Genet Epidemiol. Author manuscript; available in PMC 2015 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. GSTA1 - Maternal Main Effect Only
Maternal haplotype H showed a dominance effect that will increase the risk of disease, while 
the risk of disease was unchanged by fetal genotypes.
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Figure 2. SOD2 - Maternal Main Effect Only
Maternal haplotype H showed an additive effect that will increase the risk of disease, while 
the risk of disease was unchanged by fetal genotypes.
Li et al. Page 14
Genet Epidemiol. Author manuscript; available in PMC 2015 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. MTRR - Fetal Main Effect Only
Fetal haplotype H showed an additive effect that was protective of the disease, while the risk 
of disease was unchanged by maternal genotypes.
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Figure 4. AHCYL2 - Fetal Main Effect Only
Fetal haplotype H showed an additive effect that was protective of the disease, while the risk 
of disease was unchanged by maternal genotypes.
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Figure 5. GCLC – Both Maternal Main Effect and MFG Interaction Effect
Maternal and fetal genotypes showed interactive pattern in terms of disease risk, which is 
indicated by a pattern of “cross-over”. Maternal haplotype H also showed an additive effect 
that will increase the risk of disease.
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Figure 6. RFC1 - MFG Interaction Effect Only
Maternal and fetal genotypes showed interactive pattern in terms of disease risk.
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Figure 7. GSTM3 - MFG Interaction Effect Only
Maternal and fetal genotypes showed interactive pattern in terms of disease risk.
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Table I
Maternal Characteristics
Case
(N=331)
Control
(N=875)
Age at delivery, mean (SD) 28.4 (6.0) 27.7 (5.9)
Mother’s race
African American 23 (7%) 88 (10%)
Caucasian 237 (72%) 620 (71%)
Hispanic 51 (15%) 124 (14%)
Others 19 (6%) 42 (5%)
Missing information 1 1
Mother’s education, N (%)
<12 years 32 (10%) 117 (13%)
High school degree or equivalent 92 (28%) 209 (24%)
1–3 years of college 89 (27%) 244 (28%)
At least 4 years of college or Bachelor degree 118 (36%) 305 (35%)
Missing information 0 0
Household income, N (%)
Less than 10 Thousand 46 (15%) 112 (14%)
10 to 30 Thousand 78 (25%) 236 (29%)
30 to 50 Thousand Dollars 63 (20%) 190 (23%)
More than 50 Thousand 128 (41%) 285 (35%)
Missing information 16 52
Folic acid supplementation, N (%)
Unexposed 159 (48%) 372 (43%)
Exposed 172 (52%) 503 (57%)
Missing information 0 0
Alcohol consumption, N (%)
Unexposed 247 (75%) 681 (78%)
Exposed 84 (25%) 191 (22%)
Missing information 0 3
Cigarette smoking, N (%)
Unexposed 264 (80%) 720 (82%)
Exposed 66 (20%) 154 (18%)
Missing information 1 1
Maternal BMI, N (%)
Underweight (BMI <18.5) 13 (4%) 35 (4%)
Normal weight (18.5 <=BMI <25) 165 (51%) 462 (54%)
Overweight (25 <=BMI <30) 81 (25%) 194 (23%)
Obese (>=30) 63 (20%) 158 (19%)
Missing information 9 26
No significant differences were found between cases and controls at 5% level
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Table II
Numerical Notations for Maternal Fetal Genotype Combinations
MFG
Fetal Diplotype
HH HH̅ H̅H̅
Maternal Diplotype
HH 11 12
--
a
HH ̅ 21 22 23
H̅H ̅
--
a 32 33
aCombination not possible under Mendelian transmission
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